Opko Health Inc. (NYSE:OPK) – Stock analysts at Barrington Research issued their Q2 2017 EPS estimates for shares of Opko Health in a note issued to investors on Tuesday. Barrington Research analyst M. Petusky expects that the firm will earn ($0.01) per share for the quarter. Barrington Research also issued estimates for Opko Health’s Q3 2017 earnings at $0.00 EPS.

Other analysts have also recently issued reports about the company. Jefferies Group restated a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. Oppenheimer Holdings Inc. restated a “market perform” rating on shares of Opko Health in a research report on Thursday, August 11th. JPMorgan Chase & Co. set a $14.00 target price on Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Finally, Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 19th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $13.20.

Earnings History and Estimates for Opko Health (NYSE:OPK)

Shares of Opko Health (NYSE:OPK) opened at 9.58 on Wednesday. The stock has a 50 day moving average price of $9.93 and a 200 day moving average price of $9.89. The stock has a market capitalization of $5.27 billion and a P/E ratio of 40.08. Opko Health has a 12 month low of $7.12 and a 12 month high of $11.85.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). The company earned $298 million during the quarter, compared to analysts’ expectations of $322 million. During the same quarter in the prior year, the company earned $0.25 earnings per share. The firm’s revenue was up 108.4% compared to the same quarter last year.

In related news, CEO Phillip Md Et Al Frost acquired 48,400 shares of Opko Health stock in a transaction dated Thursday, August 25th. The stock was acquired at an average cost of $9.06 per share, with a total value of $438,504.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $27,804,696.06. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Several large investors have recently added to or reduced their stakes in OPK. California State Teachers Retirement System raised its stake in Opko Health by 6.1% in the second quarter. California State Teachers Retirement System now owns 682,157 shares of the company’s stock valued at $6,371,000 after buying an additional 39,160 shares in the last quarter. Teachers Advisors Inc. boosted its stake in shares of Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock valued at $3,379,000 after buying an additional 11,403 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Opko Health by 3.7% in the second quarter. Bank of New York Mellon Corp now owns 1,343,344 shares of the company’s stock valued at $12,547,000 after buying an additional 47,942 shares during the period. BlackRock Group LTD boosted its stake in shares of Opko Health by 19.1% in the first quarter. BlackRock Group LTD now owns 251,817 shares of the company’s stock valued at $2,616,000 after buying an additional 40,321 shares during the period. Finally, Jaffetilchin Investment Partners LLC boosted its stake in shares of Opko Health by 1.2% in the second quarter. Jaffetilchin Investment Partners LLC now owns 450,450 shares of the company’s stock valued at $4,207,000 after buying an additional 5,182 shares during the period.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.